- Home
- CRL vs IONS Comparison
CRL vs IONS Comparison
Compare CRL & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRL
- IONS
- Stock Information
- Founded
- CRL 1947
- IONS 1989
- Country
- CRL United States
- IONS United States
- Employees
- CRL N/A
- IONS N/A
- Industry
- CRL Biotechnology: Commercial Physical & Biological Resarch
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- CRL Health Care
- IONS Health Care
- Exchange
- CRL Nasdaq
- IONS Nasdaq
- Market Cap
- CRL 7.3B
- IONS 6.9B
- IPO Year
- CRL 2000
- IONS 1991
- Fundamental
- Price
- CRL $156.68
- IONS $43.78
- Analyst Decision
- CRL Buy
- IONS Buy
- Analyst Count
- CRL 14
- IONS 14
- Target Price
- CRL $186.00
- IONS $58.43
- AVG Volume (30 Days)
- CRL 1.1M
- IONS 2.0M
- Earning Date
- CRL 08-06-2025
- IONS 07-30-2025
- Dividend Yield
- CRL N/A
- IONS N/A
- EPS Growth
- CRL N/A
- IONS N/A
- EPS
- CRL N/A
- IONS N/A
- Revenue
- CRL $4,028,615,000.00
- IONS $944,050,000.00
- Revenue This Year
- CRL N/A
- IONS $9.21
- Revenue Next Year
- CRL $2.49
- IONS $14.35
- P/E Ratio
- CRL N/A
- IONS N/A
- Revenue Growth
- CRL N/A
- IONS 16.05
- 52 Week Low
- CRL $91.86
- IONS $23.95
- 52 Week High
- CRL $230.02
- IONS $50.43
- Technical
- Relative Strength Index (RSI)
- CRL 47.73
- IONS 60.61
- Support Level
- CRL $145.99
- IONS $40.37
- Resistance Level
- CRL $168.61
- IONS $41.93
- Average True Range (ATR)
- CRL 5.10
- IONS 1.42
- MACD
- CRL -1.68
- IONS -0.03
- Stochastic Oscillator
- CRL 31.41
- IONS 66.61
About CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.